Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal

Clin Cancer Res. 2013 Feb 15;19(4):755-7. doi: 10.1158/1078-0432.CCR-12-3585. Epub 2013 Feb 5.

Abstract

The search for reliable biomarkers predictive of response to anti-VEGF therapy has been elusive. VEGF-A, the therapeutic target of bevacizumab, is an intuitive candidate as a predictive biomarker to bevacizumab-based anticancer therapy. However, there remains much controversy in the use of VEGF-A as a predictor of response to bevacizumab.

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Biomarkers, Tumor / blood*
  • Carcinoma, Renal Cell / drug therapy*
  • Colorectal Neoplasms / drug therapy*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Vascular Endothelial Growth Factor A / blood*

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Vascular Endothelial Growth Factor A
  • Bevacizumab